Cosmo Pharmaceuticals NV
Company Profile
Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRLT: +353 18170370
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
339
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,053.20 | 142.30 | -1.74% |
CAC 40 | 7,834.66 | 81.42 | -1.03% |
DAX 40 | 22,260.73 | 200.79 | -0.89% |
Dow JONES (US) | 41,583.90 | 715.80 | -1.69% |
FTSE 100 | 8,593.16 | 65.69 | -0.76% |
HKSE | 23,119.58 | 307.02 | -1.31% |
NASDAQ | 17,322.99 | 481.04 | -2.70% |
Nikkei 225 | 35,617.56 | 1,502.77 | -4.05% |
NZX 50 Index | 12,270.00 | 17.46 | -0.14% |
S&P 500 | 5,580.94 | 112.37 | -1.97% |
S&P/ASX 200 | 7,843.40 | 138.60 | -1.74% |
SSE Composite Index | 3,335.75 | 15.56 | -0.46% |